Increasing the daily dose of recombinant follicle stimulating hormone (Puregon®) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation

Human Reproduction

Volumn 15, Issue 1, 2000, Pages 29-35

  Out, Henk J ^a   Braat, Didi D M ^b   Lintsen, Bea M E ^b   Gurgan, Timur ^c   Bukulmez, Orhan ^c   Gökmen, Oya ^d   Keles, G#x00FC rhan ^d   Caballero, Pedro ^e   González, José M ^e   Fábregues, Francisco ^f   Balasch, Juan ^f   Roulier, Roger ^g  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HACETTEPE UNIVERSITY   (Turkey)

^d Teaching and Research Hospital   (United Kingdom)

^e Equipo IVI Madrid   (United Kingdom)

^f DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY   (United Kingdom)

^g Institut d Endocrinologie   (United Kingdom)

Author keywords

Age; IVF; Puregon; Recombinant FSH; Trial

Indexed keywords

CHORIONIC GONADOTROPIN; FOLLITROPIN; RECOMBINANT FOLLITROPIN;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OOCYTE; OVULATION INDUCTION; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL;

EID: 0033963346     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/15.1.29     Document Type: Article

References (20)

1. Albano, C, Smitz, J., Camus, M. et al. (1996) Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix). Hum. Reprod., 11, 2114-2118.
2. Ben Rafaël, Z., Benadiva, C.A., Ausmanas, M. et al. (1987) Dose of human menopausal gonadotropin influences the outcome of an in vitro fertilization program. Fertil. Steril., 48, 964-968.
3. Coelingh Bennink, H.J.T., Fauser, B.C.J.M., Out, H.J. for the European Puregon Collaborative Anovulation Study Group (1998) Recombinant FSH (Puregon) is more efficient than urinary FSH (Metrodin) in clomipheneresistant normogonadotropic chronic anovulatory women: a prospective, multicenter, assessor-blind, randomised, clinical trial. Fenil. Steril., 69, 19-25.
4. CPMP Working Party on Efficacy of Medicinal Products (1990) Good Clinical Practice for trials on medicinal products in the European Community. Phannacol. ToxicoL, 67, 361-372.
5. Devroey, P., Toumaye, H., Van Steirteghem, A. et al. (1998) The use of a 100IU starting dose of recombinant FSH (Puregon) in in-vitro fertilization. Hum. Reprod., 13, 565-566.
6. Edwards, R.G., Lobo, RA. and Bouchard, P. (1997) Why delay the obvious need for milder forms of ovarian stimulation? Hum. Reprod., 12, 399-401.
7. Ganirelix Dose-Finding Group (1998) A double-blind, randomized, dosefinding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum. Reprod., 13, 3023-3031.
8. Hayden, C.J., Rutherford, AJ. and Baien, A.H. (1999) Induction of ovulation using a starting dose of 50 units of recombinant follicle stimulating hormone (Puregon). Fertü. Steril, 71, 106-108.
9. Jacob, S., Drudy, L., Conroy, R. and Harrison, R.F. (1998) Outcome from consecutive in vitro fertilisation/intracytoplasmic sperm injection attempts in the final group treated with urinary gonadotrophins and the first group treated with recombinant follicle stimulating hormone. Hum. Reprod., 13, 1783-1787
10. ' Land, J.A., Yarmolinskaya, M.I., Dumoulin, J.C.M. and Evers, J.L.H. (1996) High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil. Steril., 65, 961-965.
11. Matikainen, T., De Leeuw, R., Mannaerts, B. and Huhtaniemi, I. (1993) Circulating bioactive and immuno-reactive recombinant human follicle stimulating hormone (Org 32489) after administration to gonadotropindeficient subjects. Fertil. Steril., 61, 62-69.
12. Out, H.J., Mannaerts, B.M.J.L., Driessen, S.G.A.J. and Coelingh Bennink, H.J.T. (1995) A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon vs Metrodin) in in-vitro fertilization. Hum. Reprod., 10, 2534-2540.
13. Out, HJ., Lindenberg, S., Mikkelsen, A.L. et al. (1999) A prospective, randomised, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon®) in women undergoing ovarian stimulation. Hum. Reprod., 14, 622-627.
14. Pantos, C., Thomton, S.J., Speirs, A.L. and Johnston, I. (1990) Increasing the human menopausal gonadotropin dose -does the response really improve? Fertil. Steril., 53, 436-439.
15. Rongieres-Bertrand, C., Olivennes, F., Righini, C. et al. (1999) Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophinreleasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum. Reprod., 14, 683-688.
16. Scott, R.T., Toner, J.P., Muasher, S.J. et al. (1989) Follicle-stimulating hormone levels on cycle day 3 are predictive of m vitro fertilization outcome. Fertil. Steril., 51, 651-654.
17. Sharif, K., Elgendy, M., Lashen, H. and Afnan, M. (1998) Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome. Br. J. Obstet. Gynaecol., 105, 107-112.
18. Staessen, C., Camus, M., Khan, I. et al. (1989) An 18-month survey of infertility treatment by in vitro fertilization, gamete and zygote intrafallopian transfer, and replacement of frozen-thawed embryos. J. In Vitro Fertil. Embryo Transfer, 6, 22-29.
19. Toner, J.P., Philput, C.B., Jones, G.S. and Muasher, S.J. (1991) Basal follicle stimulating hormone level is a better predictor of in vitro fertilisation performance than age. Fertil. Steril., 55, 784-791.
20. Van Hooff, M.A.H. (1995) The human menopausal gonadotropin (hMG) dose in in vitro fertilization (IVF): what is the optimal dose? J. Assist. Reprod. Genet., 12, 233-235.